Pharming Group

Update in progress

PHAR (NasdaqGM)

Company RatingNeutral
SectorHealthcare
IndustryBiotechnology

Pharming Group N.V. is a biopharmaceutical company that develops and commercializes protein replacement therapies and precision medicines for rare diseases in the United States, Europe, and globally. Its lead product is RUCONEST, a recombinant C1 esterase inhibitor for acute attacks of hereditary angioedema in adults and adolescents. It also develops Joenja (leniolisib), an oral PI3K delta inhibitor for Activated PI3K Delta Syndrome. It has a collaboration with Novartis. Founded in 1988, it is headquartered in Leiden, the Netherlands.

Company score

Sentiment: 0.53; SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
Environment: 0.00; EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
Social: 0.70; SocialAssesses the company’s influence on employees, customers, communities, and wider society.−10 negative · 0 neutral · +10 positive
Governance: 0.14; GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
Sustainability: 0.24; SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
Impact Score: 0.38; Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive